Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination

Clinical and Vaccine Immunology

Volumn 14, Issue 2, 2007, Pages 115-122

  Ovsyannikova, Inna G ^a   Jacobson, Robert M ^a   Ryan, Jenna E ^a   Dhiman, Neelam ^a   Vierkant, Robert A ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; RUBELLA VACCINE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSIVE ELEMENT; FEMALE; GENETIC POLYMORPHISM; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TH1 CELL; TH2 CELL; VACCINATION;

ADOLESCENT; ANTIBODY FORMATION; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-10; POLYMORPHISM, GENETIC; RUBELLA VACCINE; TH1 CELLS; TH2 CELLS;

EID: 33947117359     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00247-06     Document Type: Article

References (47)

1. Akaboshi, I., I. Nagayoshi, M. Omura, and K. Iwaki. 2001. Elevated serum levels of interleukin-10 in children with acute rubella infection. Scand. J. Infect. Dis. 33:462-465.
2. Andrews, N., R. G. Pebody, G. Berbers, C. Blondeau, P. Crovari, I. Davidkin, P. Farrington, F. Fievet-Groyne, G. Gabutti, E. Gerike, C. Giordano, L. Hesketh, T. Marzec, P. Morgan, K. Capner, K. Osborne, A. M. Pleisner, M. Raux, A. Tischer, U. Ruden, M. Valle, and E. Miller. 2000. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol. Infect. 125:127-143.
3. Best, J. M., C. Castillo-Solorzano, J. S. Spika, J. Icenogle, J. W. Glasser, N. J. Gay, J. Andrus, and A. M. Arvin. 2005. Reducing the global burden of congenital rubella syndrome: report of the World Health Organization steering committee on research related to measles and rubella vaccines and vaccination, June 2004. J. Infect. Dis. 192:1890-1897.
4. Borish, L. 1998. IL-10: evolving concepts. J. Allergy Clin. Immunol. 101: 293-297.
5. Boulianne, N., G. De Serres, S. Ratnam, B. J. Ward, J. R. Joly, and B. Duval. 1995. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 13: 1611-1616.
6. Candore, G., D. Cigna, F. Gervasi, A. T. Colucci, M. A. Modica, and C. Caruso. 1994. In vitro cytokine production by HLA-B8, DR3 positive subjects. Autoimmunity 18:121-132.
7. Caruso, C., G. Candore, M. A. Modica, C. T. Bonanno, G. Sireci, F. Dieli, and A. Salerno. 1996. Major histocompatibility complex regulation of cytokine production. J. Interferon Cytokine Res. 16:983-988.
8. Centers for Disease Control and Prevention. 1994. Rubella and congenital rubella syndrome - United States, January 1, 1991-May 7, 1994. Morb. Mortal. Wkly. Rep. 43:391-401.
9. Centers for Disease Control and Prevention. 1998. Rubella among crew members of commercial cruise ships - Florida, 1997. Morb. Mortal. Wkly. Rep. 46:1247-1250.
10. Chu, S. Y., R. H. Bernier, J. A. Stewart, K. L. Herrmann, J. R. Greenspan, A. K. Henderson, and A. P. Liang. 1988. Rubella antibody persistence after immunization. Sixteen-year follow-up in the Hawaiian Islands. JAMA 259: 3133-3166.
11. Cutts, F. T., S. E. Robertson, J.-L. Diaz-Ortega, and R. Samuel. 1997. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull. W. H. O. 75:55-68.
12. Danovaro-Holliday, M. C., E. R. Gordon, C. Woernle, G. H. Higginbotham, R. H. Judy, J. P. Icenogle, and S. E. Reef. 2003. Identifying risk factors for rubella susceptibility in a population at risk in the United States. Am. J. Public Health 93:289-291.
13. Del Prete, G., M. de Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:353-360.
14. Dhiman, N., I. G. Ovsyannikova, R. M. Jacobson, R. A. Vierkant, S. V. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin. Immunol. 115:154-161.
15. Dhiman, N., I. G. Ovsyannikova, J. E. Ryan, R. M. Jacobson, R. A. Vierkant, S. V. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following MMR-II vaccination. Clin. Exp. Immunol. 142:498-504.
16. Fogel, A., C. B. Gerichter, B. Barnea, R. Handsher, and E. Heeger. 1978. Response to experimental challenge in persons immunized with different rubella vaccines. J. Pediatr. 92:26-29.
17. Freestone, D. S., G. M. Reynolds, J. A. McKinnon, and J. Prydie. 1975. Vaccination of schoolgirls against rubella. Br. J. Prev. Soc. Med. 29:258-261.
18. Frey, T. K., and E. S. Abernathy. 1993. Identification of strain-specific nucleotide sequences in the RA 27/3 rubella virus vaccine. J. Infect. Dis. 854:864.
19. Goodbourn, S., L. Didcock, and R. E. Randall. 2000. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81:2341-2364.
20. Greaves, W. L., W. A. Orenstein, A. R. Hinman, and W. S. Nersesian. 1983. Clinical efficacy of rubella vaccine. Pediatr. Infect. Dis. 2:284-286.
21. Grillner, L. 1975. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. Scand. J. Infect. Dis. 7:169-172.
22. Klein, J., and A. Sato. 2000. The HLA system. First of two parts. N. Engl. J. Med. 343:702-709.
23. Klein, J., and A. Sato. 2000. The HLA system. Second of two parts. N. Engl. J. Med. 343:782-786.
24. Lio, D., G. Candore, G. C. Romano, C. D'Anna, F. Gervasi, G. Di Lorenzo, M. A. Modica, M. Potestio, and C. Caruso. 1997. Modification of cytokine patterns in subjects bearing the HLA-B8, DR3 phenotype: implications for autoimmunity. Cytokines Cell. Mol. Ther. 3:217-224.
25. Mitchell, L. A., A. J. Tingle, D. Décarie, and R. Shukin. 1999. Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer. Vaccine 17: 2356-2365.
26. Mitchell, L. A., A. J. Tingle, L. MacWilliam, C. Horne, P. Keown, L. K. Gaur, and G. T. Nepom. 1998. HLA-DR class II associations with rubella vaccine-induced joint manifestations. J. Infect. Dis. 177:5-12.
27. Mosmann, T. R., and R. L. Coffman. 1989. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46:111-147.
28. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
29. Nakayama, T., T. Urano, M. Osano, M. Nakagawa, N. Maehara, K. Sasaki, and S. Makino. 1988. Production of interferon by human peripheral lymphocytes stimulated with rubella virus. Kitasato Arch. Exp. Med. 61:187-193.
30. Naniche, D., M. Garenne, C. Rae, M. Manchester, R. Buchta, S. K. Brodine, and M. B. Oldstone. 2004. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J. Infect. Dis. 190:1387-1395.
31. Orenstein, W. A., K. Herrmann, P. Albrecht, R. Bernier, P. Holmgreen, K. J. Bart, and A. R. Hinman. 1986. Immunity against measles and rubella in Massachusetts schoolchildren. Dev. Biol. Stand. 65:75-83.
32. O'Shea, S., J. M. Best, J. E. Banatvala, W. C. Marshall, and J. A. Dudgeon. 1982. Rubella vaccination: persistence of antibodies for up to 16 years. Br. J. Med. 285:253-255.
33. Ovsyannikova, I. G., R. M. Jacobson, J. E. Ryan, R. A. Vierkant, V. S. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56:798-807.
34. Ovsyannikova, I. G., R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, V. S. Pankratz, and G. A. Poland. 2004. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol. 65:1506-1515.
35. Ovsyannikova, I. G., R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, V. S. Pankratz, and G. A. Poland. 2005. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J. Infect. Dis. 191:515-519.
36. Ovsyannikova, I. G., R. M. Jacobson, N. Dhiman, J. E. Ryan, N. A. Pinsky, R. A. Vierkant, and G. A. Poland. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. G-843.
37. Paludan, S. R. 1998. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48:459-468.
38. Perkins, F. T. 1985. Licensed vaccines. Rev. Infect. Dis. 7(Suppl. 1):S73-S76.
39. Plotkin, S. A. 2001. Rubella eradication. Vaccine 19:3311-3319.
40. Plotkin, S. A. 2004. Commentary: congenital rubella syndrome should not be a disease of poor countries. Pediatr. Infect. Dis. J. 23:1123-1124.
41. Plotkin, S. A., J. D. Farquhar, and P. L. Ogra. 1973. Immunologic properties of RA27/3 rubella virus vaccine. JAMA 225:585-590.
42. Poland, G. A., and R. M. Jacobson. 1998. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10:208-215.
43. Pukhalsky, A. L., G. V. Shmarina, M. S. Bliacher, I. M. Fedorova, A. P. Toptygina, J. J. Fisenko, and V. A. Alioshkin. 2003. Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination. Mediat. Inflamm. 12:203-207.
44. Reef, S. E., T. K. Frey, K. Theall, E. Abernathy, C. L. Burnett, J. Icenogle, M. M. McCauley, and M. Wharton. 2002. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 287:464-472.
45. van der Logt, J. T., A. M. van Loon, and J. van der Veen. 1980. Replication of rubella virus in human mononuclear blood cells. Infect. Immun. 27:309-314.
46. Weibel, R. E., V. M. Villarejos, E. B. Klein, E. B. Buynak, A. A. McLean, and M. R. Hilleman. 1980. Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines. Proc. Soc. Exp. Biol. Med. 165:44-49.
47. Young, H. A., and K. J. Hardy. 1990. Interferon-gamma: producer cells, activation stimuli, and molecular genetic regulation. Pharmacol. Ther. 45: 137-151.